ARCH Venture Partners — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)Jiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)Robert Carson(Executive Officer, Director)Terry Lo(Director)Seth Benson(Executive Officer)Simona Levi(Executive Officer)
Board seatKeith Crandell· per SEC Form D
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
Austin, US
Board seatPaul Berns· per SEC Form D · $330M raise · filed Jun 2026
BiotechDurham, US
Roarke Horstmeyer(Director)Gregor Horstmeyer(Executive Officer, Director)Mark Harfouche(Executive Officer, Director)Margaret Aery(Executive Officer)Robert Horstmeyer(Director)
Board seatSean KendallPatrick Weiss· per SEC Form D · $31M raise · filed Mar 2026
SonoThera develops a nonviral, ultrasound-mediated gene delivery technology to safely deliver genetic material to targeted sites in the body.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Board seatSteven Gillis· per SEC Form D · $125.5M raise · filed Jun 2026
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.